血浆KIM-1水平与16年肾功能恶化
在基于人群的马尔默饮食与癌症研究中,基线血浆KIM-1(p-KIM-1)在4739名参与者中测定,平均随访16.6年。结果显示高p-KIM-1水平与eGFR下降更显著相关,且最高四分位组发生CKD的风险是最低四分位组的1.45倍(95%CI 1.10-1.92)。p-KIM-1可改善传统风险模型的C统计量并正确重分类9%的个体。
要点
- 高p-KIM-1水平与eGFR下降更显著相关(Q1 -1.36 vs Q4 -1.54 mL/min/1.73 m2,P<0.001)。
- 基线p-KIM-1最高四分位组发生CKD的风险是最低四分位组的1.45倍(95%CI 1.10-1.92)。
- p-KIM-1每增加1 SD,CKD风险OR 1.20(95%CI 1.08-1.33),与传统风险因素相当。
核心结论
- 在健康中年参与者中,血浆KIM-1可预测未来eGFR下降和CKD风险。
研究设计与样本
- 基于人群的马尔默饮食与癌症研究,基线(1991-1994)测定4739名参与者的血浆KIM-1,随访至2007-2012年。
主要发现
- 平均随访16.6年,高p-KIM-1水平与eGFR下降更显著相关(Q1 -1.36 vs Q4 -1.54 mL/min/1.73 m2,P<0.001)。
- 基线p-KIM-1最高四分位组发生CKD的风险是最低四分位组的1.45倍(95%CI 1.10-1.92)。
- p-KIM-1每增加1 SD,CKD风险OR 1.20(95%CI 1.08-1.33),与年龄(OR 1.55,95%CI 1.38-1.74)和收缩压(OR 1.21,95%CI 1.09-1.35)每1 SD增加的影响相当。
- 将p-KIM-1加入传统风险模型显著改善C统计量(P=0.04),并正确重分类9%的个体(连续净重分类改善P=0.02)。
- 平均随访19.2年,基线p-KIM-1每增加1 SD,因肾功能受损住院的风险HR 1.43(95%CI 1.18-1.74)。
关键数值与推荐
- CKD定义为随访时eGFR <60 mL/min/1.73 m2。
- eGFR根据CKD-EPI 2012肌酐-胱抑素C方程计算。
临床怎么用
- p-KIM-1可能作为预测未来肾功能下降和CKD风险的生物标志物,但能否用于优先预防措施尚需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The kidney injury molecule-1 (KIM-1) has previously been associated with kidney function in rodents and humans. Yet its role as a predictive marker for future decline in kidney function has remained less clear. METHODS: At baseline (1991-1994), fasting plasma KIM-1 (p-KIM-1) was measured in 4739 participants of the population-based Malmö Diet and Cancer Study. Creatinine and cystatin C were used to calculate estimated glomerular filtration rate (eGFR) according to Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Collaboration 2012 creatinine-cystatin C equation at baseline and follow-up examination (2007-2012). Incident CKD was defined as an eGFR <60 mL/min/1.73 m2 at follow-up. RESULTS: During a mean follow-up time of 16.6 years, high p-KIM-1 levels were associated with a greater decline in eGFR (quartile 1 -1.36 versus quartile 4 -1.54 mL/min/1.73 m2; P < 0.001). In multivariate analyses, the risk for incident CKD at the follow-up examination was higher among participants with baseline p-KIM-1 levels in the highest quartile {odds ratio [OR] 1.45 [95% confidence interval (CI) 1.10-1.92]} compared with those within the lowest quartile. The relative impact of baseline p-KIM-1 on incidence of CKD [OR 1.20 (95% CI 1.08-1.33) per 1 standard deviation (SD) increase in p-KIM-1] was comparable to those of age and systolic blood pressure (SBP) [OR 1.55 (95% CI 1.38-1.74) and OR 1.21 (95% CI 1.09-1.35) per 1 SD increase, respectively]. Adding p-KIM-1 to a conventional risk model resulted in significantly improved C-statistics (P = 0.04) and reclassified 9% of the individuals into the correct risk direction (continuous net reclassification improvement P = 0.02). Furthermore, the risk for hospitalization due to impaired renal function increased with increasing baseline p-KIM-1 [hazard ratio per 1 SD 1.43; (95% CI 1.18-1.74)] during a mean follow-up time of 19.2 years. CONCLUSION: Our results show that p-KIM-1 predicts the future decline of eGFR and risk of CKD in healthy middle-aged participants. Whether p-KIM-1 can be used to prioritize preventive action that needs to be further investigated.
引用
- Schulz CA, Engström G, Nilsson J, et al. Plasma kidney injury molecule-1 (p-KIM-1) levels and deterioration of kidney function over 16 years. Nephrol Dial Transplant. 2020. PMID: 30629206. doi:10.1093/ndt/gfy382
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。